Hostname: page-component-78c5997874-m6dg7 Total loading time: 0 Render date: 2024-11-15T23:37:35.456Z Has data issue: false hasContentIssue false

Study of the sexual dysfunction secondary to antidepressants in animal models

Published online by Cambridge University Press:  23 March 2020

Y. Santana Hernández*
Affiliation:
Universidad de Salamanca, Psiquiatría, Salamanca, Spain
M.V. Redondo Vega
Affiliation:
Universidad de Salamanca, Psiquiatría, Salamanca, Spain
E. Zamora Gracia
Affiliation:
Universidad de Salamanca, Psiquiatría, Salamanca, Spain
A.L. Montejo Gonzalez
Affiliation:
Universidad de Salamanca, Psiquiatría, Salamanca, Spain
J.L. Blázquez Arroyo
Affiliation:
Universidad de Salamanca, Anatomía e histología humanas, Salamanca, Spain
G. Llorca Ramón
Affiliation:
Universidad de Salamanca, Psiquiatría, Salamanca, Spain
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Sexual dysfunction is a very important problem in western countries. One of the causes is the treatment with antidepressants; most of the currently available produce sexual dysfunction in men and women (lower libido, anorgasmia, etc.).

Objective

Comparing the nervous system of the animals we expect to find differences to explain the biological substratum of the sexual dysfunction that produce the selective serotonin reuptake inhibitors.

Method

Twenty Wistar rats; approximate weight 150 g. It is divided into 4 groups: 2 experimental (paroxetine and agomelatina mouth) and 2 controls. There is a daily conduct. Weighing at the beginning of the study, 14 and 28 days. Is performed sacrifice by decapitation, is extracted from the brain and after fixing paraffin cuts are carried out for their subsequent staining (immunohistochemistry) with their corresponding murine antibody and viewing through optical microscope.

Results

Lower immunoreactivity with the antibody anti-TH in the animals treated with paroxetine, at all levels of the dopaminergic activity (tracks mesolimbica, cortical circuit, nigrostriatal pathway and tubero-infundibular). This decrease is reaffirmed after the statistical treatment of data.

Conclusions

Treatment with paroxetine in animal models causes a depletion of the dopaminergic system that can be one of the biological bases of sexual dysfunction, altering the reward mechanisms as well as producing hyperprolactinemia.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
EW649
Copyright
Copyright © European Psychiatric Association 2014
Submit a response

Comments

No Comments have been published for this article.